RUNX1T1--RUNX1

Hyperlinks to databases below
COSMIC CHIMERKB CHIMERPUB CHIMERSEQ CHITARS
FARE-CAFE TICDB TUMOR_FUSION_GDPFusionCancerConjoinG
1000Genome18CancersBodymap2HPANon_Tumor_Cells
Babiceanu_DatasetBanned_DatasetKnown_FusionsONGene DatabaseBushman Cancer Gene Database
Tumor Gene Set By UniprotOesophagus_DatasetGliomas_DatasetProstate_DatasetPancreases_Dataset
GTExKlijn_DatasetFimereli_Dataset Literature Cortex_Dataset
ChromothripsisDB

Link to Genecards:

RUNX1T1 RUNX1

COSMIC

The fusion gene pair RUNX1T1--RUNX1 information is not available in COSMIC database.

ChimerKB

Top
The fusion gene pair RUNX1T1--RUNX1 information is available in CHIMERKB (CHIMERDB 3.0) database.

Fusion_pair5'Gene Junction (Chr/Position/Strand)3'Gene Junction (Chr/Position/Strand)Breakpoint_TypeGenome_BuildDiseaseValidationPMIDGene TypeSource
RUNX1T1_RUNX1-/-/ -/-/ - hg18 acute myelogenous leukemia - 1391946 Oncogene; OMIM
RUNX1T1_RUNX1-/-/ -/-/ - hg18 leukemia - 10611307 Oncogene; OMIM

ChimerPUB

Top
The fusion gene pair RUNX1T1--RUNX1 information is available in CHIMERPUB (CHIMERDB 3.0) database.

Fusion_pairTranslocationPMIDDiseaseValidationGene TypeSentence_highlight
RUNX1T1_RUNX1t(8;21) / t(8;21) / 20046081acute myeloid leukemia;myeloid leukemia;leukemia FISH - In this case report, FISH analysis detected RUNX1-RUNX1T1 gene rearrangement in the absence of cytogenetic abnormality of t(8;21), which suggests the presence of unvailed t(8;21). /// [Near-tetraploidy acute myeloid leukemia with RUNX1-RUNX1T1 rearrangement due to cryptic t(8;21)].. /// This is the first case report of tetraploidy or near-tetraploidy AML with cryptic RUNX1/RUNX1T1 in Korea.
RUNX1T1_RUNX1t(8;21)(q22;q22) / p21;q22 / 18558290acute myeloid leukemia;myeloid leukemia;leukemia FISH - Using a dual-color FISH test with RUNX1T1 and RUNX1 probes, we demonstrated an RUNX1/RUNX1T1 fusion signal on the derivative chromosome 8, establishing this translocation as a novel complex variant of t(8;21)(q22;q22)..
RUNX1T1_RUNX1t(10;21)(q24;q22) / 21380778acute myeloid leukemia;myeloid leukemia;leukemia FISH;PCR;RT-PCR - Interphase FISH showed, in 67% of the 300 interphase nuclei analyzed, three signals for RUNX1 and two RUNX1T1, but no signals corresponding to RUNX1-RUNX1T1 fusion gene. /// "These results were corroborated by RT-PCR, which revealed negative results for the amplification of RUNX1-RUNX1T1 fusion gene. " /// Translocation (8;21)(q22;q22)/RUNX1-RUNX1T1 is a molecular marker that is usually associated with a favorable outcome in both pediatric and adult patients with acute myeloid leukemia (AML).
RUNX1T1_RUNX1t(8;21)(q22;q22) / del(5q) / del(5) / 26763368acute myeloid leukemia;myeloid leukemia;myelodysplastic syndrome;leukemia FISH - Furthermore, FISH on interphase nuclei revealed that the RUNX1/RUNX1T1 fusion signal and deletion of CSF1R signaling were found in 66.0% and 58.0% of interphase cells, respectively, suggesting that del(5)(q?) occurred in cells with RUNX1/RUNX1T1. /// "Fluorescence in situ hybridization (FISH) on metaphase spreads detected a RUNX1/RUNX1T1 fusion signal on the der(8)t(8;21)(q22;q22), and confirmed deletion of CSF1R signaling at 5q33-q34 on the del(5)(q?). "
RUNX1T1_RUNX1t(1;21;8)(q21;q22;q22) / t(8;21)(q22;q22) / t(8;21) / t(8;21) / 21325813acute myeloid leukemia;myeloid leukemia;leukemia FISH - Acute myeloid leukemia with a RUNX1-RUNX1T1 t(1;21;8)(q21;q22;q22) novel variant: a case report and review of the literature.. /// "Cytogenetic analysis revealed a karyotype of 46,XX,t(1;21;8)(q21;q22;q22), and fluorescence in situ hybridization confirmed a RUNX1-RUNX1T1 fusion signal on the derivative chromosome 8. "
RUNX1T1_RUNX1t(15;17) / t(8;21) / inv(16) / 19959801acute myeloid leukemia;myeloid leukemia;leukemia FISH - Karyotype and array technology represent genome-wide screens, whereas the other methods target specific prognostic features such as t(15;17) PML-RARA, t(8;21) RUNX1-RUNX1T1, inv(16) CBFB-MYH11, 11q23 MLL rearrangement, FLT3 internal tandem duplication, or NPM1 mutation.
RUNX1T1_RUNX1t(2;11)(q37;q23) / 19445675acute myeloid leukemia;myeloid leukemia;leukemia FISH;PCR;RT-PCR - RUNX1-RUNX1T1 (n = 12), normal karyotype (n = 11), and MLL gene fusions other than MLL-SEPT2 (n = 10).
RUNX1T1_RUNX1del(20q) / del(20)(q11.2) / 23130347acute myeloid leukemia;myeloid leukemia;leukemia FISH - Using FISH, other rearrangements such as BCR/ABL1, RUNX1/RUNX1T1, PML/RARA, CBFB/MYH11, and MLL were found to be negative.
RUNX1T1_RUNX1t(8;21) / t(8;21)(q22;q22) / t(8;21) / t(8;18;21) / p22;q11.3 / t(2;21;8) / 18p11.3 / 20417866acute myeloid leukemia;myeloid leukemia;leukemia FISH - Fluorescence in situ hybridization or reverse transcriptase-polymerase chain reaction assay confirmed the presence of RUNX1-RUNX1T1 gene (previously AML1-ETO) rearrangements.
RUNX1T1_RUNX1- 19167608acute myeloid leukemia;acute lymphoblastic leukemia;chronic myeloid leukemia FISH - Eight of these had, by interphase FISH, RUNX1/RUNX1T1 or RUNX1/ETV6 fusion, and 19 had three or more RUNX1 signals not related to fusion with RUNX1T1 or ETV6 gene. /// Bone marrow and/or peripheral blood samples were characterized using conventional G-banding techniques and fluorescent in situ hybridization (FISH) techniques with commercially available RUNX1/RUNX1T1 or ETV6/RUNX1 dual-color fusion probes.
RUNX1T1_RUNX1t(8;21) (q22;q22) / t(8;21) / 24035334acute myeloid leukemia;myeloid leukemia;leukemia FISH - In five cases with increased mast cells in which targeted-FISH analysis was performed for RUNX1-RUNX1T1, fusion signals demonstrated the translocation in mast cells in all cases. /// RUNX1-RUNX1T1..
RUNX1T1_RUNX1- 25732229acute myeloid leukemia;myeloid leukemia;leukemia FISH - Of the seven patients with favorable cytogenetics, PML/RARA, CBFB-MYH11 or RUNX1-RUNX1T1 fusion transcripts were detected at various levels in six patients but all patients remained in complete remission.
RUNX1T1_RUNX1- 21422114acute myeloid leukemia;myeloid leukemia;leukemia;hematologic malignancy FISH - 1st quartile) with those with intermediate or high expression (2nd-4th quartiles), certain mutations were observed more frequently in the former: RUNX1-RUNX1T1 (11/83, 13.3% versus 5/203.
RUNX1T1_RUNX1t(8;21)(q22;q22) / 24976338acute myeloid leukemia;myeloid leukemia;leukemia - - The RUNX1-RUNX1T1 fusion gene, a product of the nonhomologous balanced translocation t(8;21)(q22;q22), is a complex genetic locus. /// "While the RUNX1T1 gene is not expressed in normal hematopoietic cells, it may participate in t(8;21)(q22;q22)-dependent leukemic transformation due to its multiple interactions in cell regulatory network particularly through synergistic or antagonistic effects in relation to activity of RUNX1-RUNX1T1 fusion gene. "
RUNX1T1_RUNX1t(8;21) / inv(16) / t(16;16) / inv(16) / 23878140acute myeloid leukemia;myeloid leukemia;leukemia - - Since the expression of the fusion genes CBFB/MYH11 or RUNX1/RUNX1T1 alone is not sufficient to cause leukemia, we performed exome sequencing of an AML sample with an inv(16) to identify mutations, which may collaborate with the CBFB/MYH11 fusion during leukemogenesis. /// "In a cohort of 84 de novo AML patients with a CBFB/MYH11 rearrangement and in 36 patients with a RUNX1/RUNX1T1 rearrangement, the FLT3 N676K mutation was identified in 5 and 1 patients, respectively (5 [6%] of 84. "
RUNX1T1_RUNX1t(5;6)(q22;q23) / 23683787systemic mastocytosis - - In 10 cases, RUNX1-RUNX1T1 fusion gene was detected, and one patient presented with a t(5;6)(q22;q23) translocation at diagnosis.
RUNX1T1_RUNX1t(8;21) / 26361793acute myeloid leukemia;myeloid leukemia;leukemia - - We show in this study that both overexpression and knockout of microRNA (miR)-126 surprisingly result in enhanced leukemogenesis in cooperation with the t(8;21) fusion genes AML1-ETO/RUNX1-RUNX1T1 and AML1-ETO9a (a potent oncogenic isoform of AML1-ETO).
RUNX1T1_RUNX1t(8;21) / t(8;21) / 24109526granulocytic sarcoma - - This variety of AML harbors t(8;21) in up to 20-25% of cases (especially in children and black ones of African origin) and, at a molecular level, it is characterized by the generation of a fusion gene known as RUNX1-RUNX1T1.
RUNX1T1_RUNX1t(8;21) / 23528260acute myeloid leukemia;myeloid leukemia;leukemia - - The aim of this study was to evaluate effect of c-KIT mutations on RUNX1/RUNX1T1 fusion transcript expression in patients with t(8;21)-positive AML. /// Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients.. /// Patients with c-KIT mutations tended to achieve a greater than 3-log reduction in RUNX1/RUNX1T1 fusion transcript expression less frequently than patients without mutations from 6 to 12 months of follow-up.
RUNX1T1_RUNX1t(8;21) / t(8;21) / 26320575leukemia - - This translocation results in the RUNX1-RUNX1T1 fusion gene that produces a wide variety of alternative transcripts and influences the course of the disease. /// "Altogether, our results show that alternative splicing of the RUNX1-RUNX1T1 transcripts follows strict rules and that the power-law component of the fusion gene organization confers a high flexibility to this process. " /// The rules of combinatorics and splicing of exons in the RUNX1-RUNX1T1 transcripts are not known. /// "Here we show that the local exon combinatorics of the RUNX1-RUNX1T1 gene follows a power-law behavior and (i) the vast majority of exons has a low ECI, (ii) only a small part is represented by ""exons-hubs"" of splicing with very high ECI values, and (iii) it is scale-free and very sensitive to targeted skipping of ""exons-hubs"". "
RUNX1T1_RUNX1t(8;21) / 25480496- PCR - Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement..
RUNX1T1_RUNX1t(8;21)(q22;q22) / inv(16)(p13q22) / t(16;16)(p13;q22) / t(15;17)(q22;q12-21) / 18648004acute myeloid leukemia;acute promyelocytic leukemia;myeloid leukemia;leukemia - - The most frequent chromosome/molecular rearrangements, that is, t(8;21)(q22;q22)/RUNX1-RUNX1T1 and inv(16)(p13q22)/t(16;16)(p13;q22)/CBFB-MYH11 characteristic of core-binding factor (CBF) AML and t(15;17)(q22;q12-21)/PML-RARA characteristic of acute promyelocytic leukemia (APL), confer favorable clinical outcome when patients receive optimal treatment, that is, regimens that include high-dose cytarabine for CBF AML and all-trans-retinoic acid and/or arsenic trioxide for APL.
RUNX1T1_RUNX1t(9;22) / inv(16) / t(8;21) / 21275954- - - We identified five cases of Philadelphia positive subclones in AML occurring in coincidence with other genetic lesions: 1:220 patients with inv(16)/CBFB-MYH11 (0??5%), 2:272 AML cases with t(8;21)/RUNX1-RUNX1T1 (0??7%), 1:1029 NPM1-mutated AML (0??1%), and one patient with s-AML following MDS with a 5q-deletion.
RUNX1T1_RUNX1p11.2;q22 / 19596262acute myeloid leukemia;myeloid leukemia;leukemia - - A novel four-way t(6;16;21;8)(p21.3;p11.2;q22;q22) in acute myeloid leukemia with RUNX1/RUNX1T1 rearrangement..
RUNX1T1_RUNX1t(8;21)(q22;q22) / inv(16)(p13q22) / t(16;16)(p13;q22) / 25635758- - - In acute myeloid leukaemia (AML), the presence of t(8;21)(q22;q22) and inv(16)(p13q22)/t(16;16)(p13;q22) and/or the corresponding molecular rearrangements RUNX1/RUNX1T1 and CBFB/MYH11 [collectively referred to as core binding factor (CBF) AML] predict for a more favourable outcome in patients receiving cytarabine-anthracycline based induction and upon achievement of complete remission, high-dose cytarabine consolidation chemotherapy.
RUNX1T1_RUNX1t(8;21)(q22;q22) / inv(16)(p13.1;q22) / t(16;16) / p13.1;q22 / 22145956acute myeloid leukemia;myeloid leukemia;leukemia;systemic mastocytosis - - RUNX1-RUNX1T1 or inv(16)(p13.1;q22)/t(16;16)(p13.1;q22).
RUNX1T1_RUNX1t(8;21) / t(8;21) / 24616160acute myeloid leukemia;myeloid leukemia;leukemia PCR - In this study, we investigated the feasibility and performances of RUNX1-RUNX1T1 DNA as MRD marker in AML with t(8;21). /// Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.. /// RUNX1-RUNX1T1 fusion transcript is a well-established marker for minimal residual disease (MRD) monitoring. /// "Discordant MRD results were observed in 10/71 (14%) of the samples: in three samples from two patients who relapsed, RUNX1-RUNX1T1 was detectable only on DNA, while RUNX1-RUNX1T1 was detectable only on RNA in seven samples. " /// "RUNX1-RUNX1T1 MRD levels measured on DNA and RNA were strongly correlated (r = 0.8, P < 0.0001). " /// RUNX1-RUNX1T1 DNA quantification was performed by real-time quantitative PCR using patient-specific primers and probe.
RUNX1T1_RUNX1t(8;11;21)(q22;q24;q22) / 25318951acute myeloid leukemia;myeloid leukemia;leukemia - - A new complex translocation t(8;11;21)(q22;q24;q22) in acute myeloid leukemia with RUNX1/RUNX1T1..
RUNX1T1_RUNX1t(8;21) / t(8;21) (q22;q22) / t(8;21) / inv(16) / t(16;16) / 24973361acute myeloid leukemia;myeloid leukemia;leukemia - - Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations..
RUNX1T1_RUNX1t(8;21) / 26494788acute myeloid leukemia;myeloid leukemia;leukemia - - RUNX1-RUNX1T1 (formerly AML1-ETO), a transcription factor generated by the t(8;21) translocation in acute myeloid leukemia (AML), dictates a leukemic program by increasing self-renewal and inhibiting differentiation. /// Here we demonstrate that the histone demethylase JMJD1C functions as a coactivator for RUNX1-RUNX1T1 and is required for its transcriptional program. /// Analyses in JMJD1C knockout mice also establish a JMJD1C requirement for RUNX1-RUNX1T1's ability to increase proliferation. /// JMJD1C is directly recruited by RUNX1-RUNX1T1 to its target genes and regulates their expression by maintaining low H3K9 dimethyl (H3K9me2) levels.
RUNX1T1_RUNX1- 20849840hematologic malignancy PCR - We developed an allele-specific quantitative polymerase chain reaction (AS-qPCR) for FLT3 2503G>T, KIT 2446G>T, and KIT 2447A>T and compared the change in the expression levels of the FLT3 or KIT mutations assessed by AS-qPCR to those of the RUNX1-RUNX1T1 fusion gene and WT1 by conventional quantitative PCR. /// The change in the expression levels of the FLT3 or KIT mutations at the time of relapse and just after hematopoietic stem cell transplantation correlated well with that of the RUNX1-RUNX1T1 fusion gene and WT1.
RUNX1T1_RUNX1t(8;21) / inv(16) / inv(16) / 22875911- PCR;RT-PCR - At remission, after course 1 induction chemotherapy, a > 3 log reduction in RUNX1-RUNX1T1 transcripts in BM in t(8;21) patients and a > 10 CBFB-MYH11 copy number in peripheral blood (PB) in inv(16) patients were the most useful prognostic variables for relapse risk on multivariate analysis.
RUNX1T1_RUNX1t(8;21) / t(4;21;8)(q25;q22;q22) / t(4;21;8) / t(8;21)(q22;q22) / 19167612acute myeloid leukemia;myeloid leukemia;myelodysplastic syndrome;leukemia - - The presence of this novel variant of t(8;21)(q22;q22) associated with trisomy 6 may have abrogated the usual favorable prognosis associated with RUNX1T1/RUNX1 in AML.. /// RUNX1T1/RUNX1 (formerly ETO/AML1) is a molecular marker that is usually associated with a favorable outcome in both pediatric and adult patients with acute myeloid leukemia (AML). /// We describe a 10-year-old girl with AML associated with an RUNX1T1/RUNX1 fusion.
RUNX1T1_RUNX1t(8;21) / t(8;21) / del(4q) / t(9;22) / 21504717leukemia - - Instead, the Ph positive cells acquired further the t(8;21)/RUNX1-RUNX1T1, del(4q) and trisomy 15 chromosomal abnormalities which were resistant to further treatment. /// Development of t(8;21) and RUNX1-RUNX1T1 in the Philadelphia-positive clone of a patient with chronic myelogenous leukemia: additional evidence for multiple steps involved in disease progression.. /// "We conclude that there are rare patients with CML who either present in blast crisis with coexistence of t(9;22) and t(8;21) with or without +8, or progress to blast crisis with acquiring RUNX1-RUNX1T1 in the BCR-ABL1 clone which may or may not be therapy related and represent a later event in a multistep pathogenesis.. "
RUNX1T1_RUNX1t(8;21)(q22;q22) / 19167615- - - Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib..
RUNX1T1_RUNX1t(8;13;21)(q22;q33;q22) / t(8;21) / 26138995acute myeloid leukemia;myeloid leukemia;leukemia - - A Novel Three-Way Variant t(8;13;21)(q22;q33;q22) in a Child with Acute Myeloid Leukemia with RUNX1/RUNX1T1 : The Contribution of Molecular Approaches for Revealing t(8;21) Variants..
RUNX1T1_RUNX1t(15;17) / t(8;21) / inv (16) / t(16;16) / 22207733acute myeloid leukemia;myeloid leukemia;leukemia - - After excluding patients with t(15;17)/PML-RARA, t(8;21)/RUNX1-RUNX1T1, inv (16)/t(16;16)/CBFB-MYH11, and normal karyotype, 824 patients with AML with cytogenetic abnormalities were analyzed.
RUNX1T1_RUNX1t(1;21;8)(p36;q22;q22) / 19602466acute myeloid leukemia;myeloid leukemia;leukemia - - Acute myeloid leukemia (M2) with a cryptic RUNX1/RUNX1T1 t(1;21;8)(p36;q22;q22) variant..
RUNX1T1_RUNX1t(5;8)(q31;q21) / t(8;21) / t(5;8) / 19172993acute myeloid leukemia;myeloid leukemia;leukemia - - The chromosome break points of the t(8;21)(q21.3;q22.12) translocation associated with acute myeloid leukemia disrupt the RUNX1 gene (also known as AML1) and the RUNX1T1 gene (also known as CBFA2T3, MTG8 and ETO) and generate a RUNX1-RUNX1T1 fusion protein.
RUNX1T1_RUNX1t(15;17) / t(8;21) / 21387358- - - 22%) and AML with t(8;21);RUNX1-RUNX1T1 (n?=?2/21.
RUNX1T1_RUNX1t(8;21) / 24402164acute myeloid leukemia;myeloid leukemia;leukemia - - High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.. /// "Sixty-nine of 139 cases (49.6%) had 1 mutation in addition to RUNX1-RUNX1T1, and 23/139 (16.5%) had ?2 additional mutations. "
RUNX1T1_RUNX1t(8;21) / t(8;21) (q22;q22) / t(8;21) / 25082877acute myeloid leukemia;myeloid leukemia;leukemia - - We asked whether minimal residual disease (MRD) determined by RUNX1/RUNX1T1 transcript levels could identify allogeneic hematopoietic stem cell transplantation (allo- HSCT) t(8;21) (q22;q22) acute myeloid leukemia patients who are at high risk for relapse, together with the impact of c-KIT mutations. /// "In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification.. "
RUNX1T1_RUNX1t(8;21) / 23535063acute myeloid leukemia;myeloid leukemia;leukemia - - We aimed to improve the outcome of t(8;21) acute myeloid leukemia (AML) in the first complete remission (CR1) by applying risk-directed therapy based on minimal residual disease (MRD) determined by RUNX1/RUNX1T1 transcript levels.
RUNX1T1_RUNX1t(8;21) / 20075157acute myeloid leukemia;myeloid leukemia;myelodysplastic syndrome;leukemia - - We observed that both GFI1 variants maintain the same activity as transcriptional repressors but differ in their regulation by the AML1/ETO (RUNX1/RUNX1T1) fusion protein produced in AML patients with a t(8;21) translocation. /// "As a consequence, AML1/ETO does not colocalize with GFI1(36N) and is unable to inhibit its repressor activity. " /// AML1/ETO interacts and colocalizes with the more common GFI1(36S) form in the nucleus and inhibits its repressor activity.
RUNX1T1_RUNX1t(8;21) / 21488857- - - These results were confirmed and extended by demonstrating downregulation of the LAT2 protein in response to conditional RUNX1/RUNX1T1 expression, and its absence in primary AML with the t(8;21). /// "We previously identified the LAT2 gene, encoding the adaptor molecule LAT2 (NTAL, LAB), which is phosphorylated by KIT and has a role in mast cell and B-cell activation, as a target of the repressor activity of RUNX1/RUNX1T1. " /// "Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation.. " /// " The leukaemia-specific fusion oncoprotein RUNX1/RUNX1T1 (AML1/ETO), resulting from the chromosomal translocation (8;21) in acute myeloid leukaemia (AML), imposes a striking genotype-phenotype relationship upon this distinct subtype of AML, which is mediated by multiple, co-ordinate downstream effects induced by this chimeric transcription factor. "
RUNX1T1_RUNX1t(8;21)(q22;q22) / inv(16) / 17898786- - - Further, we show that overexpression of CD200 and gamma-catenin is also associated with the inv(16) abnormality which like RUNX1-RUNX1T1 disrupts core binding factor activity. /// " The t(8;21)(q22;q22) occurs frequently in acute myelogenous leukaemia and gives rise to the transcription factor fusion protein, RUNX1-RUNX1T1 (also known as AML1-ETO). " /// These data provide the most comprehensive and pertinent assessment of the effect of RUNX1-RUNX1T1 on gene expression and demonstrate the highly context-dependent effects of this fusion gene.. /// "To identify the genes dysregulated by the aberrant transcriptional activity of RUNX1-RUNX1T1, we used microarrays to determine the effect of this mutation on gene expression in human progenitor cells and during subsequent development. " /// Gene signatures of these developmental subsets were very dissimilar indicating that effects of RUNX1-RUNX1T1 are highly context dependent. /// Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia.. /// "Individually, none of these changes were sufficient to recapitulate the effects of RUNX1-RUNX1T1 on normal development. "
RUNX1T1_RUNX1- 26595813acute myeloid leukemia;acute promyelocytic leukemia;myeloid leukemia;leukemia - - While loss-of-function mutations in DNMT3A are highly recurrent in acute myeloid leukemia (AML), DNMT3A mutations are almost never found in AML patients with translocations that create oncogenic fusion genes such as PML-RARA, RUNX1-RUNX1T1, and MLL-AF9. /// "We used retroviral vectors to express PML-RARA, RUNX1-RUNX1T1, or MLL-AF9 in bone marrow cells derived from WT or DNMT3A-deficient mice. "
RUNX1T1_RUNX1t(6;9) / t(15;17) / t(8;21) / 25568664acute myeloid leukemia;myeloid leukemia;leukemia - - Until now the biology of AML-associated fusion proteins (AAFPs), such as the t(15;17)-PML/RAR?, t(8;21)-RUNX1/RUNX1T1 and t(6;9)-DEK/NUP214, all able to induce AML in mice, was investigated in different models and genetic backgrounds, not directly comparable to each other.
RUNX1T1_RUNX1t(8;16)(p11;p13) / 16849538acute myeloid leukemia;myeloid leukemia;leukemia - - MYST3-CREBBP cases clustered together and clearly differentiated from samples with PML-RARalpha, RUNX1-RUNX1T1, and CBFbeta-MYH11 rearrangements.
RUNX1T1_RUNX1- 19463768acute myeloid leukemia;myeloid leukemia;leukemia - - RUNX1/RUNX1T1 fusion transcripts of MLL gene) and for the Wilms' tumor (WT1) gene.
RUNX1T1_RUNX1inv(16) / t(4;11) / t(11;19) / 23091311- PCR - Fifteen fusion transcripts were included: BCR-ABL1, PML-RARA, ZBTB16-RARA, RUNX1-RUNX1T1, CBFB-MYH11, DEK-NUP214, TCF3-PBX1, ETV6-RUNX1, MLL-AFF1, MLL-MLLT4, MLL-MLLT3, MLL-MLLT10, MLL-ELL, MLL-MLLT1, and MLL-MLLT6.
RUNX1T1_RUNX1- 24307551hematologic malignancy;hematologic malignancy PCR - Also, we successfully assayed RUNX1-RUNX1T1 reciprocal translocations by finding both breakpoints in the Kasumi-1 cell line.
RUNX1T1_RUNX1t(8;21)(q22;q22) / 26635039acute myeloid leukemia;myeloid leukemia;leukemia PCR - A complete molecular remission was defined as a (RUNX1-RUNX1T1/ABL1)?100 ?? 0.001%.
RUNX1T1_RUNX1inv(16) / t(8;21) / 25111512- PCR - OS was not significantly different between CBF?/MYH11 (n=62) and RUNX1/RUNX1T1 (n=144), and auto-HSCT showed favorable OS compared with allo-HSCT or chemotherapy alone.
RUNX1T1_RUNX1t(8;21)(q22;q22) / 27139612acute myeloid leukemia;myeloid leukemia;leukemia - - RUNX1-RUNX1T1..
RUNX1T1_RUNX1t(8;21) (q22;q22) / t(8;21)(q22;q22) / t(8;21) / t(8;21) / 19369623acute myeloid leukemia;myeloid leukemia;leukemia - - The AML1-ETO (RUNX1-RUNX1T1) fusion was demonstrated in all 10 cases assessed.
RUNX1T1_RUNX1- 24327541acute myeloid leukemia;myeloid leukemia;leukemia - - Here we report an additional five breakpoint junction sequences from t-AML patients with the RUNX1- RUNX1T1 translocation. /// "however, the mechanism is not well understood and to date a single RUNX1-RUNX1T1 t-AML breakpoint junction sequence has been published. "
RUNX1T1_RUNX1t(8;21) / t(8;21) / 26994850acute myeloid leukemia;myeloid leukemia;leukemia - - The median fold decrease of the RUNX1/RUNX1T1 transcript level was 200 (1-358000), and 16.7% (5/30) patients achieved >3 log decrease after one cycle of the HAA regimen. /// The RUNX1/RUNX1T1 transcript level was assessed by RT-qPCR.
RUNX1T1_RUNX1- 20430445acute myeloid leukemia;myeloid leukemia;leukemia - - A novel case of acute myeloid leukemia with RUNX1/RUNX1T1 rearrangement in Klinefelter syndrome..
RUNX1T1_RUNX1- 22025082acute myeloid leukemia;myeloid leukemia;leukemia - - Submicroscopic deletion of RUNX1T1 gene confirmed by high-resolution microarray in acute myeloid leukemia with RUNX1/RUNX1T1 rearrangement..
RUNX1T1_RUNX1- 24464319acute myeloid leukemia;acute promyelocytic leukemia;myeloid leukemia;leukemia PCR;RT-PCR - Class II mutations: 24 (17.9?%), 19 (14.2?%), and 9 (6.7?%) children had PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 transcripts, respectively.
RUNX1T1_RUNX1- 23053179acute myeloid leukemia;myeloid leukemia;leukemia - - KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.. /// The unfavorable impact of D816 mutation was more prominent when the analysis was confined to the RUNX1/RUNX1T1 subtype. /// The study patients consisted of 121 patients with CBF AML (82 patients with RUNX1/RUNX1T1 [67.8?%] and 39 patients with CBFB/MYH11 [32.2?%]) recruited from eight institutions in Korea. /// "The KIT D816 mutation demonstrated an unfavorable prognostic implication, particularly in the RUNX1/RUNX1T1 subtype.. "
RUNX1T1_RUNX1- 22926532acute myeloid leukemia;myeloid leukemia;leukemia - - Pericentric chromosome 8 inversion, inv8(p11.2q22), associated with RUNX1/RUNX1T1 rearrangement in acute myeloid leukemia..
RUNX1T1_RUNX1- 22915647acute myeloid leukemia;myeloid leukemia;leukemia - - One thousand patients with cytogenetic data were investigated for the following molecular alterations: PML-RARA, RUNX1-RUNX1T1, CBFB-MYH11, FLT3-ITD, and MLL-PTD, as well as mutations in NPM1, CEPBA, RUNX1, ASXL1, and TP53. /// "(2) favorable: RUNX1-RUNX1T1 (n = 35), CBFB-MYH11 (n = 31), or NPM1 mutation without FLT3-ITD (n = 186. "
RUNX1T1_RUNX1- 23646898acute myeloid leukemia;myeloid leukemia;leukemia - - One hundred and fifty patients (median age 42?yr, range 16-69) with CBF AML (RUNX1-RUNX1T1 n?=?74.
RUNX1T1_RUNX1t(8;21)(q22;q22) / 19896694acute myeloid leukemia;myeloid leukemia;lymphoblastic leukemia;leukemia ISH - t(8;21)(q22;q22) giving rise to RUNX1/RUNX1T1 fusion transcript is a recurrent non-random chromosomal translocation, accounting for approximately 5% of cases of acute myeloid leukemia and 10% of acute myeloid leukemia with maturation. /// "Interphase and metaphase fluorescent in situ hybridization have revealed a RUNX1/RUNX1T1 fusion signal on derivative chromosome 8 but not on chromosome 21, confirming the unbalanced translocation between chromosomes 8q22 and 21q22 involving both the RUNX1 and RUNX1T1 genes. "
RUNX1T1_RUNX1t(8;21)(q22;q22) / t(8;21) / t(8;21) / 24342949acute myeloid leukemia;myeloid leukemia;leukemia - - The oncogenic fusion protein AML1-ETO, also known as RUNX1-RUNX1T1 is generated by the t(8;21)(q22;q22) translocation, one of the most frequent chromosomal rearrangements in acute myeloid leukemia (AML). /// All together our data suggest that the upregulation of PONTIN by AML1-ETO participate in the oncogenic growth of t(8;21) cells. /// "Moreover, transcriptome analysis in Kasumi-1 cells revealed a strong correlation between PONTIN and AML1-ETO gene signatures and demonstrated that PONTIN chiefly regulated the expression of genes implicated in cell cycle progression. " /// "Interestingly, AML1-ETO promoted the transcription of PONTIN. " /// Our previous studies showed that Drosophila provides a genuine model to study how AML1-ETO promotes leukemia.
RUNX1T1_RUNX1- 23358744acute myeloid leukemia;acute promyelocytic leukemia;myeloid leukemia;leukemia - - A prerequisite for individualized treatment strategies is a fast pretherapeutic molecular screening including the fusion genes PML-RARA, RUNX1-RUNX1T1 and CBFB-MYH11 as well as mutations in the genes NPM1, FLT3 and CEBPA.

ChimerSEQ

Top
The fusion gene pair RUNX1T1--RUNX1 information is available in CHIMERSEQ (CHIMERDB 3.0) database.

Fusion_pair5'Gene Junction (Chr/Position/Strand)3'Gene Junction (Chr/Position/Strand)5'Gene_locus3'Gene_locusBreakpoint_TypeGenome_BuildFrameChr_infoCancertype_or_diseaseBarcodeIDGene TypeSource
RUNX1T1_RUNX1chr8/93082830/ chr21/36219300/ 8q21.3 21q22.12 Exonic hg19 - Inter-chr NA DQ202694 Oncogene; ChiTaRs
RUNX1T1_RUNX1chr8/93087359/ chr21/36211387/ 8q21.3 21q22.12 Exonic hg19 - Inter-chr NA DQ202692 Oncogene; ChiTaRs

ChiTaRS 2.1

Top
The fusion gene pair RUNX1T1--RUNX1 information is available in CHITARS database.

OrganismChimeraIDFusion genepairHead geneTail gene
GeneChromosomeGenomic_startGenomic_stopStrandFusiongene_startposFusiongene_endpos%IdentGeneChromosomeGenomic_startGenomic_stopStrandFusiongene_startposFusiongene_endpos%Ident
Human DQ202694RUNX1T1--RUNX1 RUNX1T18 93082546 93082830 - 2 282 99.7 RUNX121 36219300 36219456 - 281 435 100
Human DQ202692RUNX1T1--RUNX1 RUNX1T18 93086896 93087359 - 3 459 99.8 RUNX121 36211387 36211486 - 460 552 100

FARE-CAFE

Top
The fusion gene pair RUNX1T1--RUNX1 information is available in FARE-CAFE.

Cancer Information
Fusion_ProteinCancer_TypeFP_Experimental_MethodFP_KaryotypeFP_Reference
RUNX1T1/ETO-RUNX1/AML1 Acute myeloblastic leukemia with maturation (FAB type M2) RT-PCR,FISH t(1;8;21)(p35;q22;q22) PubMed:18206543

Genomic Information
Fusion_ProteinFusion_Protein_Isoforms5'_ProteinF_B_PFBP_in_Exon/Intron5'_Protein_on_Positive/Negative_Strands3'_ProteinS_B_P3'_Protein_on_Positive/Negative_StrandsSBP_in_Exon/IntronFusion_Protein_mRNA_sequenceFusion_Protein_ReferenceFusion_Protein_GenbankID
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform1 RUNX1T1/ETO _ _ 0 RUNX1/AML1 _ 0 _ _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform2 RUNX1T1/ETO 93078196 0 0 RUNX1/AML1 36210851 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform3 RUNX1T1/ETO 93036241 0 0 RUNX1/AML1 36231608 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform4 RUNX1T1/ETO 93048571 0 0 RUNX1/AML1 36229667 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform5 RUNX1T1/ETO 93077244 0 0 RUNX1/AML1 36228790 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform6 RUNX1T1/ETO 93079884 0 0 RUNX1/AML1 36228030 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform7 RUNX1T1/ETO 93078477 0 0 RUNX1/AML1 36226492 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform8 RUNX1T1/ETO 93078123 0 0 RUNX1/AML1 36227448 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform9 RUNX1T1/ETO 93075859 0 0 RUNX1/AML1 36224479 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform10 RUNX1T1/ETO 93075232 0 0 RUNX1/AML1 36221875 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform11 RUNX1T1/ETO 93077511 0 0 RUNX1/AML1 36218753 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform12 RUNX1T1/ETO 93035749 0 0 RUNX1/AML1 36213728 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform13 RUNX1T1/ETO __ _ 0 RUNX1/AML1 36211736 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform14 RUNX1T1/ETO 93079698 0 0 RUNX1/AML1 36211213 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform15 RUNX1T1/ETO 93078196 0 0 RUNX1/AML1 36210870 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform16 RUNX1T1/ETO 93082695 0 0 RUNX1/AML1 36210151 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform17 RUNX1T1/ETO 93083060 0 0 RUNX1/AML1 36209454 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform18 RUNX1T1/ETO 93040039 0 0 RUNX1/AML1 36208892 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform19 RUNX1T1/ETO 93075373 0 0 RUNX1/AML1 36208571 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform20 RUNX1T1/ETO 93040039 0 0 RUNX1/AML1 36208892 0 0 _ _ _
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform21 RUNX1T1/ETO 93065785 0 0 RUNX1/AML1 36207380 0 0 _ _ _

Domains and DDI Information
Fusion_ProteinFusion_Protein_IsoformsDomains_in_5'PartnerDDIs_for_Domains_in_5'PartnerDomains_in_3'PartnerDDIs_for_Domains_in_3'Partner5'_Protein5'P_Domains5'P_Domains_DDI_partners3'_Protein3'P_Domains3'P_Domains_DDI_partnersMissing_FP_DomainsMissing_FP_Domains_DDI
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform1 - - - -RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
1) TAFH
2) NHR2
3) zf-MYND
4) Runt
5) RunxI
1) NHR2
2) Runt , CBF_beta
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform2 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform3 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform4 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform5 - - 1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform6 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform7 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform8 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform9 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform10 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform11 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform12 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform13 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform14 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform15 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform16 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform17 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform18 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform19 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform20 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -
RUNX1T1/ETO-RUNX1/AML1 RUNX1T1/ETO-RUNX1/AML1-Isoform21 1) zf-MYND
2) NHR2
3) TAFH
1) NHR2
1) Runt
1) Runt , CBF_beta
RUNX1T1/ETO 1) TAFH
2) NHR2
3) zf-MYND
1) NHR2
RUNX1/AML1 1) Runt
2) RunxI
1) Runt , CBF_beta
- -

miRNA Information
Fusion_ProteinmiRNAs_Targets_Fusion_proteinMissing_MiRNAs_Targets_Fusion_proteinFP_miRNA_Validation_method
RUNX1T1/ETO-RUNX1/AML1 hsa-miR-27a-3phsa-miR-17-5phsa-miR-20a-5phsa-miR-106a-5phsa-miR-423-5p hsa-miR-106b-5phsa-miR-183-5phsa-miR-103a-3phsa-miR-16-5phsa-let-7e-5p Report assay,Western Blot,qPCR,NGS

Transcription Factors Information
Fusion_Protein5'P_Ref_mRNA_seqIDFP_Transcription_factorsFP_Missing_TFsFP_TF_Reference
RUNX1T1/ETO-RUNX1/AML1 _ - 1) MITF_HUMAN
2) HIF1A_HUMAN
3) STAT1_HUMAN
4) RB1_HUMAN
5) RBL2_HUMAN
6) ZNF263_HUMAN
7) E2F4_HUMAN
8) P53_HUMAN
9) RUNX1_HUMAN
10) PRDM14_HUMAN
11) ESTROGEN RECEPTOR ALPHA_HUMAN
12) ETS1_HUMAN
13) EGR1_HUMAN
14) FOS_HUMAN
15) GATA2_HUMAN
16) GATA3_HUMAN
17) E2F1_HUMAN
18) SOX2_HUMAN
19) TAL1_HUMAN
20) CTCF_HUMAN
21) BRG1_HUMAN
22) HNF4A_HUMAN
23) TFAP2C_HUMAN
24) FOXA1_HUMAN
25) CEBPA_HUMAN A
26) STAT6_HUMAN A
27) ESR1_HUMAN A
28) ESR2_HUMAN A
29) AR_HUMAN A
30) MEIS1_HUMAN A
31) FOXP1_HUMAN A
32) NR1H3_HUMAN A
33) SETDB1_HUMAN A
34) SPI1_HUMAN A
35) TAL1_HUMAN A
36) TRIM24_HUMAN A
37) VDR_HUMAN
1) 21258399
2) 19828020
3) 19122651
4) 20385362
5) 20385362
6) 19887448
7) 21247883
8) 21394211
9) 20019798
10) 20953172
11) 20547749
12) 20019798
13) 20690147
14) 20139302
15) 21808000
16) 21878914
17) 21310950
18) 21211035
19) 21795385
20) 21795385
21) 19505939
22) 21646355
23) 21572391
24) 21572391
25) 20219941 A
26) 21828071 A
27) 20348243 A
28) 21235772 A
29) 21572438 A
30) 21241896 A
31) 21924763 A
32) 22292898 A
33) 21430779 A
34) 21241896 A
35) 21241896 A
36) 21164480 A
37) 21846776

TicDB

Top
The fusion gene pair RUNX1T1--RUNX1 information is not available in TicDB.

TUMOR FUSION Gene Data Portal

Top
The fusion gene pair RUNX1T1--RUNX1 information is available in TUMOR FUSION Gene Data Portal.
CancerTCGA_barcodeFusionPairEvalue5'Gene_Junction3'Gene_JunctionTierFrameTNWGS_validation
LAML AB-2875-03A RUNX1T1__RUNX1 0.56 8:93074774/-1 21:36231875/-1 tier4 In-frame 15192 NA

FusionCancer

Top
The fusion gene pair RUNX1T1--RUNX1 information is not available in FusionCancer Database.

ConjoinG

Top
The fusion gene pair RUNX1T1--RUNX1 information is not available in ConjoinG Database.

1000Genome

Top
Fusion gene RUNX1T1--RUNX1 has not been seen in a healthy sample (RNA-seq data from some samples from 1000 genomes project: Greger et al., Tandem RNA Chimeras Contribute to Transcriptome Diversity in Human Population and Are Associated with Intronic Genetic Variants, Plos One, Aug 2014 ). Therefore this candidate fusion gene has a low probability of being a false positive. [Fusion gene List compiled from FusionCatcher]

18Cancers

Top
Fusion gene RUNX1T1--RUNX1 is not found in a RNA-seq dataset of 18 types of cancers from 600 tumor samples (B. Alaei-Mahabadia et al., Global analysis of somatic structural genomic alterations and their impact on gene expression in diverse human cancers, PNAS, Nov. 2016 )

Bodymap2

Top
Fusion gene RUNX1T1--RUNX1 is not found in the list of known false positive fusion genes. The list has been generated from healthy human samples collected from 16 organs from Illumina BodyMap2 RNA-seq database. A candidate fusion gene found in this list has a very high probability of being a false positive. [Fusion gene List compiled from FusionCatcher]

HPA

Top
Fusion gene RUNX1T1--RUNX1 is not found in a healthy sample (RNA-seq database of 27 healthy tissues from 95 human individuals). A candidate fusion gene found in this dataset has a very high probability of being a false positive. [Fusion gene List compiled from FusionCatcher]

Non_Tumor_Cells

Top
Fusion gene RUNX1T1--RUNX1 was not found among the fusion genes which have been previously reported/found in non-tumor cell lines, like for example HEK293. The genes which are observed in those list can be considered as non-somatic mutation. [Fusion gene List compiled from FusionCatcher]

Babiceanu_Dataset

Top
The fusion gene pair RUNX1T1--RUNX1 information is not available in Babiceanu_Dataset.

Banned_Dataset

Top
Fusion gene RUNX1T1--RUNX1 is not found in the list of known false positive fusion genes. A candidate fusion gene found in this list has a very high probability of being a false positive. [Fusion gene List compiled from FusionCatcher]

Known_Fusions

Top
Fusion gene RUNX1T1--RUNX1 has not been found in the list of fusions previously reported or published in scientific articles/reports/books/abstracts/databases, indexed by Google, Google Scholar, PubMed, etc. The list has been manually curated by FusionCatcher software. This label has only the role to answer with YES or NO the question "has ever before a given (candidate) fusion gene been published or reported?". This label does not have in anyway the role to provide the original references to the original scientific articles/reports/books/abstracts/databases for a given fusion gene.[Fusion gene List compiled from FusionCatcher]

ONGene Database

Top
The head gene RUNX1T1 is a known oncogene according to ONGENE database.


The tail gene RUNX1 is a known oncogene according to ONGENE database.

Bushman Cancer Gene Database

Top
The head gene RUNX1T1 is cancer associated according to Bushman Cancer Gene database.


The tail gene RUNX1 is cancer associated according to Bushman Cancer Gene database.

Tumor Gene Set By Uniprot

Top
The head gene RUNX1T1 is proto-oncogene or tumor suppresor gene according to Uniprot database.


The tail gene RUNX1 is proto-oncogene or tumor suppresor gene according to Uniprot database.

Oesophagus_Dataset

Top
Fusion gene RUNX1T1--RUNX1 is not found in oesophageal tumors from TCGA samples, which are published here.

Gliomas_Dataset

Top
Fusion gene RUNX1T1--RUNX1 is not found in the RNA-seq dataset of 272 glioblastomas, published here.

Prostate_Dataset

Top
The fusion gene pair RUNX1T1--RUNX1 information is not available in Prostate Dataset (150 prostate tumor RNAs, Robison et al, Integrative Clinical Genomics of Advanced Prostate Cancer, Cell, Vol. 161, May 2015, http://dx.doi.org/10.1016/j.cell.2015.05.001).

Pancreases_Dataset

Top
Fusion gene RUNX1T1--RUNX1 is not found in pancreatic tumor dataset, published here.

GTEx

Top
Fusion gene RUNX1T1--RUNX1 has not been found in a healthy sample (GTEx database of healthy tissues (thru FusionAnnotator)). A candidate fusion gene found in this set has a very high probability of being a false positive. [Fusion gene List compiled from FusionCatcher]

Klijin_Dataset

Top
The fusion gene pair RUNX1T1--RUNX1 information is not available in Klijn Dataset.

Fimereli_Dataset

Top
The fusion gene pair RUNX1T1--RUNX1 information is not found in Fimereli_Dataset.

Literature

Top
The fusion gene pair RUNX1T1--RUNX1 information is not found in known fusion genelist compiled from literature.

Cortex_Dataset

Top
Fusion gene RUNX1T1--RUNX1 is not found in Cortex_Dataset (Fusion genes found in healthy human brains (BA9 prefrontal cortex)) . A candidate fusion gene found in this dataset has a very high probability of being a false positive.

ChromothripsisDB

Top
The fusion gene pair RUNX1T1--RUNX1 information is not available in ChromothripsisDB database.